Compare · AVTR vs WAT
AVTR vs WAT
Side-by-side comparison of Avantor Inc. (AVTR) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $35.87B, about 5.7x AVTR ($6.25B).
- WAT has been more active in the news (7 items in the past 4 weeks vs 3 for AVTR).
- Both have 25 recent analyst ratings on file.
- Company
- Avantor Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $6.25B
- $35.87B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- 1995
- News (4w)
- 3
- 7
- Recent ratings
- 25
- 25
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest AVTR
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
- Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)
- Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)
- Director Massaro Joseph R was granted 25,270 shares, increasing direct ownership by 48% to 77,408 units (SEC Form 4)
- Director Makin Louise was granted 25,270 shares, increasing direct ownership by 116% to 47,140 units (SEC Form 4)
Latest WAT
- Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
- Wolfe Research resumed coverage on Waters with a new price target
- Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
- Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
- SEC Form SD filed by Waters Corporation
- SEC Form 8-K filed by Waters Corporation
- Waters Corporation to Present at the Jefferies Global Healthcare Conference
- SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Waters Corporation
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition